Optimal Medical Therapy Is a Proven Option for Chronic Stable Angina  by O'Rourke, Robert A.
D
m
a
n
(
a
E
a
e
T
A
l
p
p
a
M
t
P
P
w
F
T
Journal of the American College of Cardiology Vol. 52, No. 11, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
POptimal Medical Therapy
Is a Proven Option for Chronic Stable Angina
Robert A. O’Rourke, MD, MACP, MACC, FAHA
San Antonio, Texas
The authors of the meta-analysis of a percutaneous coronary intervention (PCI)-based invasive strategy for
improving prognosis for the treatment of angina conclude that a pooling of data from various studies can
be sufficiently powered to evaluate the impact of PCI on long-term mortality. However, most randomized
coronary artery patient trials have insufficient power to detect significant differences in hard end points.
Randomized trials in patients with chronic stable angina enroll few patients who are over age 65 years,
have depressed ventricular function, have clinical instability, or who have undergone previous coronary ar-
tery bypass grafting (CABG) or PCI. “Medical therapy” today no longer means the absence of PCI, but rather
the presence of intensive, evidence-based pharmacologic intervention. The COURAGE (Clinical Outcomes
Utilizing Revascularization and Aggressive druG Evaluation) trial randomized 2,287 patients to optimal
medical therapy alone or optimal medical therapy plus PCI. Optimal medical therapy consisted of anti-
platelet therapy, anti-ischemic therapy, and aggressive lipid and blood pressure control. Based on the
strength of the evidence, the author of this commentary recommends more-aggressive medical therapy for
patients with moderate-to-severe angina, and PCI or CABG for many patients in whom symptoms persist.
Optimal medical therapy is a proven option for chronic stable angina. (J Am Coll Cardiol 2008;52:905–7)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.015i
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iuring the past 4 decades, there have been many improve-
ents in our therapeutic options for patients with coronary
rtery disease. We have better cardiac surgical techniques,
ew and improved percutaneous coronary interventions
PCIs), and advances in the medical treatment of coronary
therosclerosis, including therapy for modifiable risk factors.
ffective drugs that improve prognosis include antiplatelet
gents, statins, beta blockers, and angiotensin-converting
nzyme inhibitors (1–5).
herapeutic Options Currently Available
ccording to the recommendations of the American Col-
ege of Cardiology/American Heart Association clinical
ractice guidelines (4), the 3 major options for treating
atients with coronary artery disease include medical ther-
py only, PCI, and coronary artery bypass grafting (CABG).
edical therapy is necessary whether or not revasculariza-
ion is performed.
CI
ercutaneous coronary intervention is indicated in patients
ith acute coronary syndromes in whom revascularization
rom the University of Texas Health Science Center at San Antonio, San Antonio,S
exas. Dr. O’Rourke is a co-principal investigator of the COURAGE trial.
Manuscript received May 23, 2008; accepted June 2, 2008.mproves long-term prognosis (6–8). Percutaneous coro-
ary intervention is the most popular revascularization
rocedure used to treat stable angina and angina equiva-
ents; however, it may not be necessary for many patients
ith chronic stable coronary artery disease but no acute
oronary syndromes. The impact of PCI on the long-term
rognosis of these patients is still not well defined. Al-
hough drug-eluting and bare metal stents are highly effec-
ive in treating severe coronary stenoses, they do not treat
therosclerosis beyond the stenotic coronary segment in
hich they are implanted.
andomized Clinical Trials
f PCI Versus Medical Therapy
atients with stable coronary artery disease have a very good
ong-term prognosis, and large sample sizes are required to
eparate potential differences in treatment regarding un-
ommon events. Most randomized coronary artery patient
rials performed to date have insufficient power to predict
ard end points (5). The recurring question about all
andomized studies is whether or not the results can be
eneralized to less selective patient populations in practice
ettings. Randomized trials in patients with coronary artery
isease have enrolled few patients who were over 65 years of
ge, had depressed left ventricular function, had clinical
nstability, or who had undergone previous CABG or PCI.
ome trials have failed to define the medical therapy that
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risk factor control during the
study. “Medical therapy” today no
longer means the absence of PCI,
but rather the presence of inten-
sive, evidence-based pharmaco-
logic and lifestyle interventions.
The results of randomized trials
o not necessarily apply to other populations that are not
ell represented because of the small number randomized.
he COURAGE Trial
he COURAGE (Clinical Outcomes Utilizing Revascular-
zation and Aggressive druG Evaluation) trial randomized
,287 patients to optimal medical therapy alone or optimal
edical therapy plus PCI (3). There was objective evidence
f ischemia and extensive angiographic disease as well as a
igh prevalence of comorbidity. Optimal medical therapy
onsisted of antiplatelet therapy, anti-ischemic therapy, and
ggressive lipid and blood pressure control. The projected
omposite 3-year event rate was 21% in the optimal medical
herapy group and 16.4% in the PCI group (relative differ-
nce: 22%) during a follow-up period of 2.5 to 7 years (3).
he statistical analysis estimated that the enrollment of
,270 patients would provide a power of 85% to detect the
nticipated difference in the primary outcome at the 5%
-sided level of significance (3). Estimates of the cumulative
vent rate were calculated by the Kaplan-Meier method (3).
he primary efficacy of PCI as compared with optimal
edical therapy was assessed by the stratified log-rank
tatistic (3).
The 4.6-year cumulative primary event rate was 19% in
he PCI group and 18.6% in the medical therapy group
hazard ratio [HR] for the PCI group: 1.05, 95% confidence
nterval [CI]: 0.87 to 1.27; p  0.620) (3). There were 85
eaths (7.6%) in the PCI group and 95 deaths (8.3%) in the
edical therapy group (HR: 0.87, 95% CI: 0.65 to 1.16;
 0.38). Although the degree of angina relief was
ignificantly higher in the PCI group, there was also
ubstantial improvement in the optimal medical therapy
roup. During the trial, 33% of the optimal medical therapy
roup crossed over to revascularization, but 67% did not.
any were asymptomatic on optimal medical therapy.
hese findings reinforce clinical practice guidelines (1),
hich state that PCI can be safely deferred in patients with
table angina.
In the COURAGE trial, more uniform data and consis-
ent selection criteria were used than is possible in a
eta-analysis. Only patients undergoing a prescribed diag-
ostic workup were randomized. An important lesson from
he COURAGE trial is that therapeutic options should be
eviewed with the patient with an emphasis on patient
reference and quality of life because deferral of PCI did not
arry a penalty in terms of survival or nonfatal myocardial
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
PCI  percutaneous
coronary interventionnfarction. aeta-Analysis
eta-analysis combines and summarizes available evidence
uantitatively. Although it can be used to combine nonran-
omized studies, meta-analysis is most valuable when used
o summarize all the randomized trials addressing a partic-
lar therapeutic problem (9–11). Furthermore, the best
eta-analyses obtain and analyze the raw patient-level data
9), rather than working with only what is available in the
ublished forms of each trial. Ideally, meta-analysis permits
he aggregation of lesser-powered studies into one analysis
owered to detect a significant difference between treat-
ents. Well-defined inclusion criteria relevant to the ques-
ion to be asked and comprehensive accounting for all
tudies using these criteria are critical to the success of any
eta-analysis addressing this issue. Importantly, not all
ublished meta-analyses are reliable sources of evidence on
particular clinical problem. The method of analysis must
e carefully examined to define proper study design and
nalysis (9). The results of a well-done meta-analysis are
ikely to be more meaningful if the analysis includes at least
everal large-scale, properly performed randomized trials.
Meta-analyses typically focus on summary measures of
reatment benefit, such as odds ratios or relative risks.
linicians should also consider what absolute risk reduction
an be expected from the therapy.
eta-Analysis of PCI
n this issue of the Journal, Schömig et al. (5) pooled
ogether the results of 17 randomized trials comparing PCI
nd medical treatment as strategies in patients with stable
ngina and no acute coronary syndromes. The purpose of
his meta-analysis was to evaluate whether PCI affects
ong-term survival of patients with stable coronary artery
isease (5). The meta-analysis intended to include all
tudies that investigated the relative merit of PCI in patients
ith stable coronary artery disease and “symptoms or signs”
f ischemia. Trials were accepted or excluded depending on
hether specific relevant data were available. Intention-to-
reat was the method of analysis. The number of patients
ncluded in the 17 trials ranged from 44 to 2,287 (the
OURAGE trial).
The primary end point of the meta-analysis was all-cause
eath. Other outcomes of interest were cardiac-caused
eath and nonfatal myocardial infarction. The randomiza-
ion follow-up ranged between 12 and 122 months (average
1 months). The analysis was performed according to the
reatment group; 3,675 patients were assigned to the PCI-
ased treatment group and 3,838 to the medical treatment
roup. There was no significant difference across the trial
egarding mortality. However, allocation to the PCI group
as associated with a 20% reduction in the odds ratio of
ll-cause death (odds ratio: 0.08, 95% CI: 0.64 to 0.99). In
ddition, randomization to the PCI groups was associated
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September 9, 2008:905–7 Coronary Artery Disease: A Commentaryith a nonsignificant reduction in the odds ratio for cardiac
eath.
There are several important limitations to this study by
chömig et al. (5). The methods of diagnosing myocardial
schemia, the extent of coronary artery disease, and the
resence of periprocedural or spontaneous myocardial in-
arction in individual patients and subgroups are not given.
he odds ratios from mortality in individual trials with 95%
onfidence intervals are large. Patient-level data were not
nalyzed. Some studies included patients with recent myo-
ardial infarction who were not clearly in a stable phase of
heir disease, threatening the generalizability of the findings
o patients with stable coronary disease. There was a large
ariability in the comprehensiveness and intensity of sec-
ndary prevention provided to patients, calling into question
he appropriateness of combining data from such different
herapeutic regimens. Therefore, these findings using a
eta-analysis instead of a large randomized controlled trial
uggest but do not establish that the PCI-based invasive
trategy may improve long-term survival compared with
edical treatment strategy in stable coronary artery disease.
he difference between the findings of the meta-analysis
nd the COURAGE trial may be attributable to a difference
n the accuracy of the data being analyzed, with patient-level
ata from a large randomized controlled trial being superior.
urthermore, the distinctly aggressive and comprehensive
nti-atherothrombotic medical therapy delivered in the
OURAGE trial may also explain the difference.
onclusions
he investigators of the meta-analysis conclude that a
CI-based invasive strategy may improve long-term survival
n patients with stable coronary artery disease, and that this
ustifies a new clinical trial sufficiently powered to evaluate
he impact of PCI on long-term mortality. Based on the
trength of the evidence, the author of this commentary
ecommends more aggressive medical therapy for patients
ith moderate to severe angina, and PCI or CABG for
atients whose symptoms persist. Optimal medical therapy
s a proven option for chronic stable angina.
K
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